Comparison of clinical features in the training and validation cohorts of patients with advanced-stage FL
. | Validation cohort (R-CHOP) . | Training cohort (MCP/CHOP) . | P . | ||||
---|---|---|---|---|---|---|---|
Count . | % . | n . | Count . | % . | n . | ||
GLSG1996 Trial | 0 | 0 | 274 | 141 | 52 | 273 | |
GLSG2000 Trial | 274 | 100 | 132 | 48 | <.001 | ||
Males | 130 | 47 | 274 | 136 | 50 | 273 | .61 |
Stage IV disease | 180 | 66 | 271 | 179 | 66 | 273 | .86 |
BM involved | 165 | 63 | 261 | 167 | 61 | 272 | .72 |
Affected LN regions >4 | 181 | 69 | 261 | 183 | 67 | 272 | .64 |
B symptoms present | 113 | 42 | 271 | 119 | 44 | 272 | .66 |
ECOG score | |||||||
0 | 91 | 35 | 266 | 85 | 32 | 268 | .73 |
1 | 149 | 58 | 160 | 60 | |||
2 | 18 | 7 | 21 | 8 | |||
3 | 0 | 0 | 1 | 0 | |||
4 | 0 | 0 | 1 | 0 | |||
Elevated LDH | 78 | 30 | 261 | 72 | 27 | 271 | .44 |
Hb <120 g/L | 52 | 19 | 267 | 53 | 19 | 272 | >.99 |
FLIPI | |||||||
Low | 34 | 14 | 248 | 40 | 15 | 269 | .93 |
Intermediate | 106 | 43 | 112 | 42 | |||
High | 108 | 44 | 117 | 43 | |||
Underwent first-line ASCT | 73 | 27 | 274 | 65 | 24 | 273 |
. | Validation cohort (R-CHOP) . | Training cohort (MCP/CHOP) . | P . | ||||
---|---|---|---|---|---|---|---|
Count . | % . | n . | Count . | % . | n . | ||
GLSG1996 Trial | 0 | 0 | 274 | 141 | 52 | 273 | |
GLSG2000 Trial | 274 | 100 | 132 | 48 | <.001 | ||
Males | 130 | 47 | 274 | 136 | 50 | 273 | .61 |
Stage IV disease | 180 | 66 | 271 | 179 | 66 | 273 | .86 |
BM involved | 165 | 63 | 261 | 167 | 61 | 272 | .72 |
Affected LN regions >4 | 181 | 69 | 261 | 183 | 67 | 272 | .64 |
B symptoms present | 113 | 42 | 271 | 119 | 44 | 272 | .66 |
ECOG score | |||||||
0 | 91 | 35 | 266 | 85 | 32 | 268 | .73 |
1 | 149 | 58 | 160 | 60 | |||
2 | 18 | 7 | 21 | 8 | |||
3 | 0 | 0 | 1 | 0 | |||
4 | 0 | 0 | 1 | 0 | |||
Elevated LDH | 78 | 30 | 261 | 72 | 27 | 271 | .44 |
Hb <120 g/L | 52 | 19 | 267 | 53 | 19 | 272 | >.99 |
FLIPI | |||||||
Low | 34 | 14 | 248 | 40 | 15 | 269 | .93 |
Intermediate | 106 | 43 | 112 | 42 | |||
High | 108 | 44 | 117 | 43 | |||
Underwent first-line ASCT | 73 | 27 | 274 | 65 | 24 | 273 |
ASCT, autologous stem cell transplantation; BM, bone marrow; ECOG, Eastern Cooperative Oncology Group; FLIPI, FL International Prognostic Index; Hb, hemoglobin; LDH, lactate dehydrogenase; LN, lymph node.